Company
Teva Pharmaceuticals
758 Legal Matters
179
145
434

Teva Pharmaceuticals Company IP Overview

Practice Areas
Recent StatisticsView All
Subscription-Only
View Concierge Program
PatentsView All
Patents Issued Each Year
TrademarksView All
Trademark Applications Filed Each Year
LitigationView All
Cases Filed Each Year
Mikele Bicolli
UroGen Pharma Faces Paragraph IV Challenge as Teva Pursues Generic Jelmyto Approval
Mikele Bicolli
Mar 1, 2024
Shares of UroGen Pharma (NASDAQ: URGN) took a minor premarket hit following news that Teva Pharmaceutical (NYSE: TEVA) has submitted... Read More
Mikele Bicolli
Corcept Therapeutics Faces Share Price Plunge After Losing Teva Patent Battle
Mikele Bicolli
Jan 2, 2024
  Corcept Therapeutics experienced a significant drop in its stock value by 27% on Tuesday following an unfavorable verdict in... Read More
Pedram Sameni
Patexia Insight 192: Top Brand and Generic Companies in ANDA 2023
Pedram Sameni
Nov 9, 2023
In August, our much-anticipated fourth annual ANDA Litigation Intelligence Report made its entrance into the world of pharmaceutical litigation. This... Read More
Practice Areas
PatentsView All
Patents Issued Each Year
LitigationView All
Cases Filed Each Year
Recent StatisticsView All
Subscription-Only
View Concierge Program
TrademarksView All
Trademark Applications Filed Each Year
Mikele Bicolli
UroGen Pharma Faces Paragraph IV Challenge as Teva Pursues Generic Jelmyto Approval
Mikele Bicolli
Mar 1, 2024
Shares of UroGen Pharma (NASDAQ: URGN) took a minor premarket hit following news that Teva Pharmaceutical (NYSE: TEVA) has submitted... Read More
Mikele Bicolli
Corcept Therapeutics Faces Share Price Plunge After Losing Teva Patent Battle
Mikele Bicolli
Jan 2, 2024
  Corcept Therapeutics experienced a significant drop in its stock value by 27% on Tuesday following an unfavorable verdict in... Read More
Pedram Sameni
Patexia Insight 192: Top Brand and Generic Companies in ANDA 2023
Pedram Sameni
Nov 9, 2023
In August, our much-anticipated fourth annual ANDA Litigation Intelligence Report made its entrance into the world of pharmaceutical litigation. This... Read More